It took just over three decades for exosomes to move from a laboratory curiosity to a validated biological system with real therapeutic potential. First formally named in 1981 and identified in sheep reticulocytes in 1983, exosomes weren’t seriously investigated for medical application until the late 2000s and early 2010s, once researchers discovered they could shuttle transferable mRNA and miRNA between cells. That shift was cemented in 2013, when the Nobel Prize in Physiology or Medicine was awarded to Rothman, Schekman, and Südhof for validating the mechanisms behind vesicular transport. [Read more…]

In the evolving landscape of biomedical innovation, exosomes have emerged as one of the most promising tools for next-generation therapies. These nanoscale, membrane-bound vesicles, naturally secreted by cells, play a critical role in intercellular communication. Because of their inherent ability to shuttle biomolecules like RNA, proteins, and lipids between cells, exosomes have captivated the attention of researchers and biotech companies for their vast potential in therapeutic applications. [Read more…]

Since 2010, exosome companies have quietly built a private capital base exceeding $600M, closed at least five strategic acquisitions in the past three years alone, and struck licensing agreements with milestone structures reaching as high as $1B. None of this activity has produced a single IPO yet, which makes the financing story here unusual: a maturing industry building its capital structure almost entirely through venture rounds, acquisitions, and platform licensing rather than public markets. [Read more…]